Obiageli Ogbata, MD, FACP
May, 2022
Obiageli U Ogbata, MD FACP
Novant Health Weisiger Cancer Institute
125 Queens Road, Suite # 400,
Charlotte, NC 28204
Email: ouogbata@novanthealth.org
EDUCATION AND TRAINING:
INSTITUTION AND LOCATION | DEGREE | END DATE MM/YY | FIELD OF STUDY |
College of Medicine, University of Nigeria, Enugu State, Nigeria | MBBS | 06/2003 | Medicine/Surgery |
University of Nigeria Teaching Hospital, Enugu State, Nigeria | Internship | 08/2004 | Internal Medicine |
Newark Beth Israel Medical Center, Newark, New Jersey | Residency | 07/2010 | Internal Medicine |
University of Tennessee Health Science Center (UTHSC), Division of Hematology/Medical Oncology, Memphis, TN | Fellowship | 06/2014 | Hematology/Oncology |
PROFESSIONAL EXPERIENCE:
Head & Neck/Thoracic Medical Oncologist,
Novant Health Cancer Institute
125 Queens Road,
Suite # 400, Charlotte, NC 28204
11/2020 – current
Hematologist/Medical Oncologist,
Novant Health Cancer Specialists
1718 East 4th Street, Suite # 707, Charlotte, NC 28204
08/2017 – 10/2020
Hematologist/Medical Oncologist,
Levine Cancer Institute - Cleveland, (Atrium Health South-East),
201 East Grover Street, Shelby, NC 28150
08/2014 – 05/2017
Hospitalist Physician,
Carolinas Hospitalist Group,
Carolinas Medical Center, (now Atrium Health)
1000 Blythe Blvd, Charlotte, NC 28203
09/2010 - 06/2011
RESEARCH EXPERIENCE:
Principal Investigator, active
EA5182 – A Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Principal Investigator, active
E4512 - A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Principal Investigator, active
A151216 - Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) A Companion Protocol to Alliance A081105 and ECOG E4512, Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Principal Investigator, closed to accrual
KEYNOTE B10 - A Phase 4, single-arm, open-label clinical study of pembrolizumab (MK-3475) to evaluate the efficacy and safety of MK-3475 plus carboplatin and paclitaxel as first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma
Principal Investigator, active EA3161 - A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPSCCa
Principal Investigator, active INTERLINK 1 – A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor Principal Investigator, closed to accrual EA5142 - Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-small Cell Lung Cancers |
HOSPITAL AFFILIATIONS:
Novant Health Presbyterian Medical Center,
200 Hawthorne Lane, Charlotte, NC 28204
BOARD CERTIFICATION:
Board Certified in Internal Medicine, August 2010, recertified 2021, active
Board Certified in Hematology, November 2014, active
Board Certified in Medical Oncology, November 2014, active
POSITION, HONORS AND AWARDS:
Clinical Assist Professor of Medicine, UNC School of Medicine, Mar 2022
Co – Chair, Head, Neck, and Thyroid Committee, Elsevier Clinical Pathway, Sep 2021
Secretary, Association of Nigerian Physicians in the Americas, Carolinas Chapter, Jan 2021
Fellow, American College of Physicians, July 2017
Outstanding Fellow of the Year Award in Hematology/Medical Oncology Fellowship, University of Tennessee Health Science Center, Memphis, TN. June 2014
University of Tennessee Cancer Center Trainee Research Award/grant ($10,000) - recipient, January 2013
National Merit Award, American Society of Clinical Oncology, June 2012
Certificate of Appreciation for going far and beyond expectations, Veterans Affairs Medical Center, Memphis, TN, awarded in 2011, 2012 and 2013
Resident of the Year Award in Internal Medicine, Newark Beth Israel Medical Center, Newark, New Jersey, June 2010
2nd Best Graduating Student, Class of 2001, College of Medicine, Univ of Nigeria, June 2003
Best Academic performance in Internal Medicine, 5th MBBS Professional Exam, May 2003
Best Academic performance in Pediatrics, 4th MBBS Professional Exam, October 2002
Dean’s list throughout medical school, (1995 – 2003)
ABSTRACTS AND PUBLICATIONS:
Obiageli U Ogbata, David C. Portnoy. Non-operative management of patients with carcinoma metastatic to bone. The Journal of Current Orthopaedic Practice. Vol 25, No 6. November/December 2014.
Ogbata, O U, Yang, C, Pfeiffer, L et al; Using microRNA(miRNA) profiling to differentiate noninvasive and muscle invasive from metastases of transitional cell carcinoma of the urinary bladder (TCC-UB). Funded by The University of Tennessee Cancer Center Research grant. Poster presented at ASCO – GU symposium Jan/Feb 2014.
Osarogiagbon, R U, Ogbata, O U, Yu, X; The number of lymph nodes associated with maximal reduction of longterm mortality risk in pathologic node-negative non-small lung cancer. The Annals of Thoracic Surgery. February 2014 (97), Issue 2, 385 – 393).
M S Walker, A Masaquel, J Kerr, D Lalla, D Abidoye, O U Ogbata, L S Schwartzberg; Real World Symptom Burden and early Treatment Discontinuation in 1st Line Metastatic Breast Cancer. Poster presented at ASCO Annual Meeting in Chicago, 2013.
Ogbata, O U, Yu Xinhua, Osarogiagbon R; Prognostic impact of the number of examined lymph nodes in resected node negative ( pN0)-NSCLC – a SEER analysis. Presented during a Poster discussion session at ASCO Annual Meeting in Chicago, June 3, 2012. Earned the National Merit Award.
L Elreda, O U Ogbata, M Drejka, A J Cohen; Factor XI activity is not predictive of Thrombin Generation – Poster presented at Congress of the International Society of Thrombosis and Haemostasis, July 15 2009 in Boston, Massachusetts.
Ojukwu O U, Okoli C B, Onyeaso N; Incidence of Childhood Malignancies in Eastern Nigeria; Annals of the University of Nigeria. Sept 15, 2002.
APPOINTMENTS:
Clinical Assist Professor of Medicine,
University of North Carolina School of Medicine, 03/2022 - current
Co-Chair,
Elsevier ClinicalPath Head, Neck, and Thyroid Oncology Committee, 09/2021 - current
Lead Clinician, Head & Neck Cancer Clinic, 01/2021 - current
Novant Health Weisiger Cancer Institute
Head & Neck Tumor Council, Co-Lead (Lead for Greater Charlotte Market)
Novant Health Cancer Institute 08/2019 - current
Section Chief, Department of Medicine 11/2016 – 05/2017
CHS – Cleveland (Atrium Health South East)
Member, Practice Site Lead Physician Committee 02/2016 – 05/2017
Levine Cancer Institute
Class Leader, 2001 class 2002 - 2003
College of Medicine, University of Nigeria
Director, Medical Research and Humanitarian Society 2001 - 2003
University of Nigeria College of Medicine
PROFESSIONAL SOCIETIES:
Member, American Society of Clinical Oncology 2011- active
Member, American Society of Hematology 2011 - active
Member, International Association on Study for Lung Cancer 2011 - active
Member, American College of Physicians 2007 - active
Member, Association of Nigerian Physicians in the Americas (ANPA) 2005 - active
HOBBIES:
In my spare time, I enjoy listening to music, playing and watching soccer, spending time with and traveling with family.
Obiageli U. Ogbata, M.D., FACP
Financial relationships
-
Type of financial relationship:There are no financial relationships to disclose.Date added:05/16/2022Date updated:05/16/2022
**Disclaimer**
This Continuing Medical Education (CME) Learning Management System, Ethos, includes individuals designated as 'faculty' for CME purposes. Please note that the term 'faculty' refers solely to their role as a contributor/planner within a CME activity and does not imply any formal affiliation with UT Southwestern Medical Center (UTSW). The display of names and credentials is intended for educational purposes only and does not necessarily indicate a professional or academic relationship with UTSW. Participants are encouraged to verify the affiliations and credentials of faculty members independently if further clarification is needed.